The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations.
 
Siamak Daneshmand
Stock and Other Ownership Interests - Taris
Honoraria - Aduro Biotech; Allergan (I); Bristol-Myers Squibb; Ferring; Janssen; Johnson & Johnson; Nucleix; Olympus; pacific edge; Photocure; QED Therapeutics; Seagen; Spectrum Pharmaceuticals
Consulting or Advisory Role - Ferring; Photocure; QED Therapeutics; Taris
Research Funding - Photocure
Travel, Accommodations, Expenses - Photocure
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genzyme; GlaxoSmithKline; HERON; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Roche; Seagen
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Immunomedics (Inst); Pfizer (Inst)
 
Srikala S. Sridhar
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst); Janssen (Inst); Pfizer (Inst)
 
Shilpa Gupta
Stock and Other Ownership Interests - Nektar
Honoraria - AstraZeneca; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Merck Sharp & Dohme; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Janssen Oncology
Research Funding - Astellas Medivation (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
 
Joaquim Bellmunt
Stock and Other Ownership Interests - Rainier Therapeutics
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Pfizer/EMD Serono (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; MSD Oncology; Pfizer
 
Guru Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Agensys; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech; Janssen; Merck; Novartis
Speakers' Bureau - Onclive; Physicans' Education Resource; Research to Practice
Research Funding - AstraZeneca; Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Janssen (Inst); Merck (Inst); Onyx (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group; QED Therapeutics
 
Mark T. Fleming
Employment - Virginia Oncology Associates
Consulting or Advisory Role - Janssen Oncology
Speakers' Bureau - Genentech; Janssen Oncology
Travel, Accommodations, Expenses - Genentech; Medivation/Astellas
 
Seth P. Lerner
Honoraria - Dava Oncology; MSD; Nucleix
Consulting or Advisory Role - Anchiano; Ferring; Merck Sharp & Dohme; miR Scientific; QED Therapeutics; Roche/Genentech; Urogen pharma; Vaxiion; Verity Pharmaceuticals
Research Funding - Endo Pharmaceuticals; FKD Therapies; Japan BCG Laboratory; Roche/Genentech; Urogen pharma; Vaxiion; Viventia Biotech
Patents, Royalties, Other Intellectual Property - TCGA expression subtype singel patient classifier
Travel, Accommodations, Expenses - Dava Oncology; Ferring; MSD; Nucleix
 
Yohann Loriot
Honoraria - Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Janssen; Janssen (Inst); MSD Oncology; MSD Oncology (Inst); Roche; Seagen
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); CureVac (Inst); Exelixis (Inst); Incyte (Inst); Janssen Oncology (Inst); Medivation (Inst); MSD Oncology (Inst); Nektar (Inst); Oncogenex (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Hao Wang
Employment - QED Therapeutics
 
Hiywot Takkele
Employment - QED Therapeutics
 
Corina Andresen
Employment - QED Therapeutics
Stock and Other Ownership Interests - QED Therapeutics
Honoraria - QED Therapeutics
Travel, Accommodations, Expenses - QED Therapeutics
 
Jessica Rearden
Employment - Merck (I); QED Therapeutics
Stock and Other Ownership Interests - Merck (I)
 
Craig Berman
Employment - QED Therapeutics
 
Sumanta K. Pal
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation